Tech Company Financing Transactions
Opsidio Funding Round
On 9/26/2017, Opsidio raised funding from BioAdvance Ventures and private investors.
Transaction Overview
Company Name
Announced On
9/26/2017
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
BioAdvance Ventures (Lead Investor) (Gregory Harriman)
Proceeds Purpose
Opsidio will use the funds to prepare the lead drug candidate for manufacturing, and plan to be in clinical testing within two years.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
223 Ladbroke Rd.
Bryn Mawr, PA 19010
USA
Bryn Mawr, PA 19010
USA
Phone
Email Address
Not Recorded
Overview
Opsidio, LLC is a preclinical stage biopharmaceutical company developing monoclonal antibodies to treat fibrotic diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Martin Phillips
Browse more venture capital transactions:
Prev: 9/26/2017: Nanoport venture capital transaction
Next: 9/26/2017: IsoPlexis venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs